(Q46734875)

24 December 2017

title

Dabrafenib: first global approval (English)

1 reference

24 December 2017

main subject

dabrafenib mesylate

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

2

1 reference

24 December 2017

author name string

Anita D Ballantyne

series ordinal

1

1 reference

24 December 2017

publication date

1 August 2013

1 reference

24 December 2017

published in

Drugs

1 reference

24 December 2017

volume

73

1 reference

24 December 2017

issue

12

1 reference

24 December 2017

page(s)

1367-1376

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.1007/s40265-013-0095-2

exact match

0 references

cites work

Novel targets in the treatment of advanced melanoma: new first-line treatment options

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0095-2

Update on the targeted therapy of melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0095-2

Which drug, and when, for patients with BRAF-mutant melanoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0095-2

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0095-2

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0095-2

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0095-2

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0095-2

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0095-2

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0095-2

BRAF inhibitor activity in V600R metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0095-2

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0095-2

Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23881668

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40265-013-0095-2

1 reference

24 December 2017

PubMed ID

23881668

1 reference

24 December 2017